Lynn van Olst, PhD: No financial relationships to disclose
Learning Objectives:
Upon completion, participant will be able to describe the implications and historical context of the AN1792 amyloid-β immunotherapy trial in Alzheimer's disease treatment, including its after-effects and the reasons for its termination.
Upon completion, participant will be able to explain the methodology and utility of spatial transcriptomics in analyzing RNA from cortical brain sections, as well as how this approach was utilized to examine a unique cohort of immunized and non-immunized Alzheimer's patients.
Upon completion, participant will be able to interpret and analyze the genetic signatures found in the study, including their association with amyloid-β clearance, tau propagation, meningeal and neuroinflammation, and their potential impact on future Alzheimer's disease therapies.
